Skip to content
Hanzhang Liu
Hanzhang Liu

Hanzhang Liu

Data Scientist
Johnson & Johnson’s
Bio

Hanzhang is the Lead Data Scientist at Johnson & Johnson’s, where she has been driving optimization and simulation-based decision-making for nearly seven years. She specializes in network optimization, maximizing capacity utilization while minimizing costs, and currently leads J&J’s Digital Value Chain Options Modeling capabilities—leveraging Digital Twin simulation and advanced analytics to optimize global supply chain strategies.
Hanzhang has played a key role in enhancing J&J’s supply chain resilience, driving initiatives that have led to millions in cost avoidance, reduced cycle times, and improved strategic decision-making. She collaborates closely with cross-functional teams, bridging data science with business strategy to enable smarter, more proactive supply chain planning.
She holds a master’s degree in industrial and systems engineering from Lehigh University and is passionate about using data-driven solutions to solve complex operational challenges. Sally is also an advocate for knowledge-sharing, contributing to the growth of data science talent within J&J and beyond.


Optimizing Supply Chains with Digital Twins: A Path to Resilience, Agility, and Strategic Advantage

In today’s rapidly evolving healthcare landscape, supply chain optimization is more critical than ever. This presentation delves into the transformative potential of Digital Twins—virtual models of real-world processes—designed to tackle the complexities of growing customer demands, regulatory shifts, and operational inefficiencies.
We will explore how Digital Twin simulation is revolutionizing J&J’s supply chain by enabling proactive, data-driven decision-making. Key challenges—fragmented data, strategy limitations, and capability constraints—will be addressed through the Value Chain Options Modeling capabilities. By leveraging standardized models, dynamic simulations, and predictive analytics, we have achieved millions in cost avoidance, a 40% increase in manufacturing throughput, and up to a 50% reduction in cycle time.
Looking ahead, we will continue to scale these capabilities, enhance agility, and drive long-term resilience—ensuring that life-saving medicines reach patients faster, more efficiently, and with greater confidence.

Professional / Leadership